The U.S. Department of Defense has recently awarded contracts to several companies in support of Medical Countermeasures Product Research and Development.
The period of performance for the effort is a base period of 5 years with a budget of $500,001,000. Five 1-year option periods, if exercised, could bring the total contract value is $900,000,000.
Task orders can be of the following types and will be determined per requirement at the task order level: Firm Fixed Price, Fixed Price Incentive Fee, Cost Plus Fixed Fee, Cost Plus Incentive Fee, Cost Plus Award Fee, or Time and Materials.
The selected awardees are:
- Dynport Vaccine Company
- PPD Development
- TASC Inc.
- Leidos Inc.
The overall objective is to facilitate the timely and efficient execution of the U.S. Army’s medical materiel development program by providing a mechanism for advanced medical product development and life cycle support, including pharmaceutical manufacturing and clinical research.